LATEST PSYCHEDELICS STOCKS NEWS

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Dec. 02, 2022 -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce tha... Read More...

Global MDF Market to Reach $96.5 Bn, Globally, by 2031 at 6.0% CAGR: Allied Market Research

Rise in global population, increasing urbanization, and surge in tourism across the world have significantly increased the demand for residential and non-residential buildings, which in turn has fueled the use of medium density fiberboard (MDF), as it is majorly used in flooring, door and windows, and in interior designing of buildings. T... Read More...

BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona

VANCOUVER, British Columbia, Dec. 02, 2022 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that one of its scientific collaborators, Dr. Argel Aguil... Read More...

Red Light Holland Reports Second Quarter 2023 Financial Results

Cash balance of $20.5 million as at September 30, 2022Revenue of $736 thousand (2021 - $485 thousand)Property and equipment value of $4.7 millionTotal assets of $31.2 millionNet loss for the quarter was $1.3 million, or ($0.00) per share (2021 - $1.8 million, or ($0.01) per share)Acquisition of MiniChamp B.V., a grow at home mushroom kit ... Read More...

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

TORONTO, Nov. 30, 2022 -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) is pleased to announce that it is arranging a private placement of a minimum of $3 million and up to $5 million of units (each, a “Unit”), at a price of $0.15 per Unit; (the “Offering”). The Offering is being led by EMD Financial Inc. E... Read More...

Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130

Vancouver, British Columbia--(Newsfile Corp. - November 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced an update for its clinical development plans for its p... Read More...

GOODMIND™ Available for Sale in the United Kingdom and Europe – Exclusive Distribution Agreement Concluded With This Works

TORONTO, Nov. 29, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), ente... Read More...

Field Trip Health & Wellness Ltd. Announces Updated Time for Fiscal Second Quarter 2023 Financial Results and Conference Call

TORONTO, Nov. 28, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" of “Field Trip”), a global leader in the delivery of psychedelic therapies, announced today that it now plans to release financial results for its fiscal 2023 second quarter for the three-month period ended September 30, 2022, after market close on... Read More...

Bright Minds Biosciences Announces Non-Brokered Private Placement

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Nov. 28, 2022 -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce a n... Read More...

Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, Nov. 24, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it will submit the Type C meeting request package to the U.S. Food &a... Read More...

Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, Nov. 22, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has responded that a ... Read More...

Field Trip Health & Wellness Ltd. Strengthens Leadership Team With Two Executive Appointments, Schedules Fiscal Second Quarter 2023 Conference Call

Appoints Stacey Hoisak as Senior Vice President, General Counsel, and Dr. Monique Moller as Vice President, Integrative HealthSchedules Fiscal Second Quarter 2023 Conference Call for Tuesday, November 29, 2022, at 8:30 AM ET TORONTO, Nov. 22, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), a glo... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022

VANCOUVER, BC, Nov. 22, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Thursday, Dece... Read More...

Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement

DENVER, Nov. 21, 2022 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in con... Read More...

Pure Extracts Receives Approval from Manitoba Liquor & Lotteries to list Pure Pulls Vapes and Pure Chews Edibles

VANCOUVER, British Columbia, Nov. 16, 2022 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and functional mushrooms, is pleased to announce that its wholly-owned subsidiary, Pure Extracts Manufacturing Corp., has rece... Read More...

Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

TORONTO, November 15, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 20... Read More...

Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022

DENVER, Nov. 14, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported company highlights and financial results for the nine months ended September 30, 2022. Company Highlights In 2022, Mydecin... Read More...

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine. The ob... Read More...

Miami on November 3-5, 2022

 VANCOUVER, BC, Oct. 31, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Wonderland: Miami hosted by Microdose to be held at the Mana Wynwood Convention Cent... Read More...

Delic Labs President and CSO Dr. Markus Roggen to Discuss the Importance of R&D for Business Growth at MJBizCon

Dr. Markus Roggen, President and Chief Science Officer for Delic Labs, will participate in a panel discussion about building scientific trust and using research and development to differentiate a brand and maximize revenuesVANCOUVER, BC, Oct. 27, 2022 - Delic Holdings Corp ("Delic") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new m... Read More...

COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022

COMPASS PathwaysLONDON, Oct. 26, 2022 -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2022, and provide an update on recent business developments on 3 Nov... Read More...

Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study

ENGLEWOOD CLIFFS, NJ, Oct. 20, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD), as... Read More...

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics

ENGLEWOOD CLIFFS, NJ, Oct. 18, 2022 -- Silo Pharma, Inc. (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced it has entered into an agreement with Columbia University pursuant to which Silo has been granted an extension for i... Read More...

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

TORONTO, Oct. 14, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has finalized an amended protocol to the U.S. Food & Drug Admi... Read More...

Lobe Sciences Announces the Completion of cGMP Production of Clinical Supplies For Upcoming Clinical Trials

Appointment of Philip J. Young, CEO, as Board ChairmanVancouver, British Columbia--(Newsfile Corp. - October 13, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it... Read More...

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Studies of SP-26, the company’s proprietary, time-released ketamine show positive results in reducing neuropathic nerve pain  ENGLEWOOD CLIFFS, NJ, Oct. 10, 2022 --  Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, toda... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022

VANCOUVER, BC, Oct. 7, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a Water Tower Research Fireside Chat on Thur... Read More...

Lobe Sciences Announces the Appointment of Baxter F. Phillips III to Its Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - October 5, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that Baxter F. Phillips III has been appointed to the Board of... Read More...

Pure Extracts Receives Purchase Order for a New Listing of Cured Resin Vape Carts from the Ontario Cannabis Store

VANCOUVER, British Columbia, Oct. 05, 2022 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and functional mushrooms, is pleased to announce that its wholly-owned subsidiary, Pure Extracts Manufacturing Corp., has rece... Read More...

Field Trip Health & Wellness to Participate in the Cantor Fitzgerald Symposium on Mental Health Clinics on October 11th

TORONTO, Oct. 04, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), a global leader in psychedelic therapies, today announced it will participate in a virtual fireside chat at Cantor Fitzgerald’s “Symposium on Mental Health Clinics,” taking place on Tuesday, October 11, 2022. Mujeeb Jafferi, Presi... Read More...

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine ENGLEWOOD CLIFFS, NJ, Oct. 03, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it is working ... Read More...